TRACON Pharmaceuticals Inc. (NASDAQ:TCON) Relative Strength Index (RSI) is 45.29, with weekly volatility at 4.36% and ATR at 0.16. The TCON stock’s 52-week price range has touched low of $0.95 and a $8.90 high. Intraday shares traded counted 0.12 million, which was 60.1% higher than its 30-day average trading volume of 305.53K. Its shares traded lower over the last trading session, losing -1.52% on 06/23/20. The shares fell to a low of $1.95 before closing at $1.95. TCON’s previous close was $1.98 while the outstanding shares total 5.17M. The firm has a beta of 2.05.
Investors have identified the Biotechnology company TRACON Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $10.76 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
TRACON Pharmaceuticals Inc. (TCON) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For TCON, the company has in raw cash 14.13 million on their books with 1.27 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on a decline. In terms of their assets, the company currently has 14969000 million total, with 8772000 million as their total liabilities.
Potential earnings growth for TRACON Pharmaceuticals Inc. (TCON)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, TRACON Pharmaceuticals Inc. recorded a total of 3.88 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -84.42% coming in sequential stages and their sales for the third quarter increasing by 1.85%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent -3.88 million trying to sell their products during the last quarter, with the result yielding a gross income of 0.13 million. This allows shareholders to hold on to 5.17M with the revenue now reading -0.78 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (-0.99 cents a share).
Having a look at the company’s valuation, the company is expected to record -7.47 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TCON sounds very interesting.
Is the stock of TCON attractive?
In related news, Director, PELLETIER SAUNDRA L bought 3,000 shares of the company’s stock in a transaction that recorded on Jun 15. The purchase was performed at an average price of 2.07, for a total value of 6,209. As the purchase deal closes, the Director, PELLETIER SAUNDRA L now bought 2,500 shares of the company’s stock, valued at 5,000. Also, President and CEO, THEUER CHARLES bought 10,592 shares of the company’s stock in a deal that was recorded on May 22. The shares were cost at an average price of 1.90 per share, with a total market value of 20,119. Following this completion of disposal, the President and CEO, THEUER CHARLES now holds 4,100 shares of the company’s stock, valued at 4,624. In the last 6 months, insiders have changed their ownership in shares of company stock by 1.30%.